10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2018-08-14 (Q2 2018) | Holdings: 119 | Value: $13.3B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seattle Genetics, Inc. | New Purchase | 25.46% | $3.4B | -26.41% | +3.79% | ||
| INCY - Incyte Corporation | New Purchase | 17.24% | $2.3B | -3.64% | -3.69% | +19.39% | |
| BGNE - BeiGene, Ltd. | New Purchase | 13.81% | $1.8B | +51.30% | -21.75% | -13.01% | |
| ALXN - Alexion Pharmaceuticals, Inc. | New Purchase | 7.98% | $1.1B | +0.66% | -8.29% | ||
| BMRN - BioMarin Pharmaceutical Inc. | New Purchase | 5.37% | $714.3M | -43.22% | -7.36% | -29.87% | |
| GHDX - Genomic Health, Inc. | New Purchase | 5.22% | $695.0M | +49.55% | +39.91% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | New Purchase | 3.12% | $415.8M | +50.73% | +30.19% | +102.80% | |
| MDGL - Madrigal Pharmaceuticals, Inc. | New Purchase | 2.46% | $327.0M | +17.84% | -43.19% | -61.49% | |
| HRTX - Heron Therapeutics, Inc. | New Purchase | 1.47% | $195.2M | -95.24% | -29.49% | -57.22% | |
| ASND - Ascendis Pharma A/S | New Purchase | 1.42% | $188.7M | +138.66% | -14.98% | +68.27% | |
| MRTX - Mirati Therapeutics, Inc. | New Purchase | 0.93% | $123.9M | -33.05% | +55.51% | ||
| ONCE - Spark Therapeutics, Inc. | New Purchase | 0.86% | $114.6M | -35.73% | +64.98% | ||
| DBVT - DBV Technologies S.A. | New Purchase | 0.80% | $106.3M | -95.53% | -12.43% | -53.03% | |
| SAGE - Sage Therapeutics, Inc. | New Purchase | 0.72% | $96.0M | -95.66% | -24.89% | +8.11% | |
| ARRY1 - Array BioPharma Inc. | New Purchase | 0.71% | $94.9M | ||||
| NBIX - Neurocrine Biosciences, Inc. | New Purchase | 0.70% | $92.8M | +6.63% | -20.51% | -17.76% | |
| RYTM - Rhythm Pharmaceuticals, Inc. | New Purchase | 0.64% | $84.7M | +104.50% | -8.47% | -33.71% | |
| BCRX - BioCryst Pharmaceuticals, Inc. | New Purchase | 0.60% | $80.3M | +53.79% | +4.58% | -63.09% | |
| ARGX - argenx SE | New Purchase | 0.60% | $79.7M | +561.12% | +5.90% | +55.39% | |
| CERS - Cerus Corporation | New Purchase | 0.54% | $71.7M | -82.48% | -26.90% | -28.14% | |
| AMRN - Amarin Corporation plc | New Purchase | 0.53% | $70.0M | -80.29% | +502.72% | +391.16% | |
| CBAY - CymaBay Therapeutics, Inc. | New Purchase | 0.50% | $66.0M | -23.26% | -52.43% | ||
| NVTA - Invitae Corporation | New Purchase | 0.46% | $61.7M | +28.23% | +144.23% | ||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | New Purchase | 0.39% | $52.0M | +76.52% | +17.10% | -39.29% | |
| IDRA - Idera Pharmaceuticals, Inc. | New Purchase | 0.38% | $51.0M | -13.14% | -75.35% | ||
| TCDA - Tricida, Inc. | New Purchase | 0.36% | $47.8M | +28.72% | +38.89% | ||
| GWPH - GW Pharmaceuticals plc | New Purchase | 0.34% | $44.9M | -2.33% | +14.59% | ||
| N/A - Novavax, Inc. | New Purchase | 0.32% | $42.7M | ||||
| ABEO - Abeona Therapeutics Inc. | New Purchase | 0.26% | $35.0M | -98.07% | -37.84% | -83.24% | |
| PHXM - ERYTECH Pharma S.A. | New Purchase | 0.26% | $34.5M | -26.80% | -48.00% | ||
| XNCR - Xencor, Inc. | New Purchase | 0.24% | $32.3M | -80.44% | -4.74% | -1.39% | |
| ECYT - Endocyte, Inc. | New Purchase | 0.24% | $31.4M | +44.94% | |||
| BLUE - bluebird bio, Inc. | New Purchase | 0.24% | $31.4M | -99.75% | -21.07% | -24.79% | |
| BLCM - Bellicum Pharmaceuticals, Inc. | New Purchase | 0.23% | $30.2M | -29.62% | -84.33% | ||
| NLTX - Aquinox Pharmaceuticals, Inc. | New Purchase | 0.22% | $29.0M | ||||
| MRUS - Merus N.V. | New Purchase | 0.20% | $26.4M | +202.26% | -23.23% | -12.67% | |
| GLPG - Galapagos NV | New Purchase | 0.18% | $24.0M | -72.24% | -0.22% | +63.65% | |
| QURE - uniQure N.V. | New Purchase | 0.17% | $22.9M | -60.03% | -14.56% | +54.75% | |
| HALO - Halozyme Therapeutics, Inc. | New Purchase | 0.16% | $21.7M | +224.48% | -6.25% | -8.28% | |
| MYOK - MyoKardia, Inc. | New Purchase | 0.16% | $21.5M | +2.53% | -4.22% | ||
| SLDB - Solid Biosciences Inc. | New Purchase | 0.16% | $20.9M | -99.45% | -20.20% | -84.17% | |
| ZYME - Zymeworks Inc. | New Purchase | 0.15% | $19.4M | -18.94% | -8.58% | +77.30% | |
| SGMO - Sangamo Therapeutics, Inc. | New Purchase | 0.14% | $18.2M | -97.13% | -36.05% | -31.79% | |
| AIMT - Aimmune Therapeutics, Inc. | New Purchase | 0.14% | $18.1M | +4.60% | -22.95% | ||
| INSM - Insmed Incorporated | New Purchase | 0.12% | $16.6M | +232.52% | -19.69% | -26.13% | |
| CFRX - ContraFect Corporation | New Purchase | 0.12% | $15.8M | +4.98% | -80.50% | ||
| CMTA - Clementia Pharmaceuticals Inc. | New Purchase | 0.12% | $15.7M | +75.61% | |||
| N/A - BioMarin Pharmaceutical Inc. | New Purchase | 0.11% | $15.2M | ||||
| BOLD - Audentes Therapeutics, Inc. | New Purchase | 0.11% | $15.0M | ||||
| NTLA - Intellia Therapeutics, Inc. | New Purchase | 0.11% | $15.0M | -75.38% | -37.92% | -39.43% | |